Pirlimycin (Synonyms: U-57930E) |
Catalog No.GC12836
One-Click Copy Product Info
|
lincosamide antibiotic
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 79548-73-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Pirlimycin, a lincosamide antibiotic, is effective against gram-positive bacteria, including Staphylococcus, Bacteroides, Streptococcus, and Plasmodium. It functions via inhibiting protein synthesis in bacteria by inducing premature dissociation of the peptidyl-tRNA from the ribosome.
In vitro: Pirlimycin showed activity against Helicobacter pylori with a minimal inhibitory concentration [MIC] 50 of 4 μg/ml and an MIC90 of 64 μg/ml [1].
In vivo: Cows were treated with 50 mg of pirlimycin via two intramammary infusions per quarter at a 24- hour interval (2-day) for 2, 5, or 8 days. Pirlimycin showed antibiotic therapy against environmental Streptococcus spp and Staphylococcus aureus intramammary individual and combined infections [1]. Specifically, pirlimycin cured environmental Streptococcus spp infections in 66.7% (14/21), 85% (17/20), 100% (14/14) in the 2-day group, 5-day group and 8-day group, respectively. S. aureus infections were cured by the treatment of pirlimycin in 13.3% (2/15), 31.3% (5/16), 83.3% (5/6) in the 2-day group, 5-day group and 8-day group, respectively. Furthermore, S. aureus, S. dysgalactiae subsp dysgalactiae, and Enterococcus spp intramammary infections were eliminated by the extended treatment of pirlimycin in 8-day group [2].
References:
[1]. Westblom, T., Midkiff, B., & Czinn, S. In vitro susceptibility ofHelicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A). European Journal of Clinical Microbiology & Infectious Diseases. 1993; 12(7): 560-562.
[2]. B. E. Gillespie, H. Moorehead, P. Lunn, H. H. Dowlen, D. L. Johnson, K. C. Lamar, M. J. Lewis, S. J. Ivey, J. W. Hallberg, S. T. Chester, and S. P. Oliver. Efficacy of extended pirlimycin hydrochloride therapy for treatment of environmental Streptococcus spp and Staphylococcus aureus intramammary infections in lactating dairy cows. Veterinary Therapeutics. 2002; 3(4): 373-80.
| Cas No. | 79548-73-5 | SDF | |
| Synonyms | U-57930E | ||
| Chemical Name | methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-4-ethyl-2-piperidinyl]carbonyl]amino]-1-thio-L-threo-α-D-galacto-octopyranoside | ||
| Canonical SMILES | CC[C@@H]1CCN[C@H](C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O)C1 | ||
| Formula | C17H31ClN2O5S | M.Wt | 411 |
| Solubility | Soluble in ethanol; methanol; DMSO; dimethyl formamide; water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4331 mL | 12.1655 mL | 24.3309 mL |
| 5 mM | 486.6 μL | 2.4331 mL | 4.8662 mL |
| 10 mM | 243.3 μL | 1.2165 mL | 2.4331 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)